ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV

▴ ViiV Healthcare Announces First Global Regulatory Approval
CABENUVA reduces treatment dosing days from 365 to 12 per year ​

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that Health Canada has approved CABENUVA, the first and only once-monthly, complete long-acting regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral (ARV) regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]). VOCABRIA oral tablets, to be used for short time periods in conjunction with CABENUVA, have also been approved by Health Canada. These approvals are the first for CABENUVA and VOCABRIA anywhere in the world.


CABENUVA allows virologically suppressed adults living with HIV to maintain viral suppression while reducing their dosing schedule from 365 days to 12 days per year. VOCABRIA and CABENUVA should not be used in patients with known or suspected resistance to cabotegravir or rilpivirine. A kit with two injectable medicines—ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine— CABENUVA was co-developed as part of a collaboration with Janssen and builds on ViiV Healthcare’s industry-leading portfolio centered on delivering innovative medicines for the HIV community.


Deborah Waterhouse, CEO, ViiV Healthcare, said: “Today’s approval marks a monumental step in the treatment of HIV and is a true testament to ViiV Healthcare’s R&D innovation. With CABENUVA, people living with HIV who are virologically suppressed now have an option to maintain that suppression with 12 treatments a year thereby positively impacting their lives.”


The approval of CABENUVA is based on the pivotal phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) studies that included more than 1,100 participants from 16 countries.1,2 Prior to initiating treatment with CABENUVA, oral dosing of cabotegravir and rilpivirine lead-in was administered for approximately one month to assess the tolerability of cabotegravir and rilpivirine. The studies demonstrated that CABENUVA, when injected intramuscularly in the buttocks, once a month, was as effective as continuing their daily, oral, antiretroviral regimens in maintaining viral suppression throughout the 48-week study period.


In both studies, the most common adverse reactions (Grades 1 to 4) observed in ≥ 2% of participants receiving CABENUVA were injection site reactions, pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, rash, and diarrhoea. Over the 48-week study period, a total of 4% of participants discontinued CABENUVA due to adverse events.3 TheNew England Journal of Medicine published the 48-week results of these studies in its March 4, 2020 issue.


CABENUVA was preferred over their previous daily oral therapy by approximately 9 out of 10 patients who switched to cabotegravir and rilpivirine long-acting in ATLAS and FLAIR studies. Treatment preference data was collected from ATLAS and FLAIR clinical trial participants who received CABENUVA. In a pooled exploratory analysis of this Intent-to-Treat Exposed (ITT-E) population, 532 participants completed a single-item question at Week 48 (59 participants did not) and 88% (523/591) preferred CABENUVA compared with 2% (9/591) who preferred their previous ARV treatment. The results were descriptive in nature and are not intended to infer clinical significance.4


Chloe Orkin, M.D., Consultant Physician and Clinical Professor at Queen Mary University of London and FLAIR principal investigator, said: “CABENUVA, an injectable treatment, has the potential to transform HIV care by offering monthly instead of daily treatment to suitable patients. It reduces the frequency of dosing and is as effective as daily, oral, three-drug regimens in maintaining viral suppression among adults living with HIV. Most participants in the clinical trials preferred it over their prior oral daily regimens.”

Tags : #Viivhealthcare #Cabenuva #Hivdrug #Newapproval

About the Author


Team Medicircle

Related Stories

26 Feb

Did the Government Force Covid Vaccines Without Responsibility? The Supreme Court Thinks So

Will the government take responsibility, or will affected families be left fighting a lonely legal battle? The coming weeks will determine the course of justice for those who lost loved ones in the fight against COVID-19.

View
19 Dec

Why Your Blood Pressure Reading Might Be a Lie and How to Fix It

By breaking the cycle of ignorance and inaccuracy, we can turn the tide against hypertension, ensuring healthier lives for generations to come.

View
12 Dec

Plastic Pollution Goes Personal: Microplastics Found in Human Blood

This study serves as both a warning and an opportunity, a chance to rethink our relationship with plastic and prioritize the health of our planet and ourselves.

View
14 Nov

Not a Fan of Exercise? Here’s How Few Steps You Actually Need for Better Health

By embracing simple, consistent movements, each one of us has the power to boost our health, reduce our risk of disease, and live a longer, happier life.

View
09 Nov

The Deadly 17: WHO’s Vaccine Priority List to Tackle Life-Threatening Infections

By focusing on these 17 high-priority pathogens, WHO is leading the way for a world that is better prepared, more resilient, and healthier for all.

View
10 Oct

DKMS BMST Foundation India Expands Stem Cell Donor Registry with 400+ New Donors registered from IIT Delhi

DKMS BMST Foundation India, a non-profit organization dedicated to the fight against blood cancer and disorders collaborated with IIT Delhi’s cultural festival Rendezvous 2024 as the social initiative partner, driving an impactful stem cell donor registration campaign that garnered an overwhelming participation, with over 400 students registering as potential stem cell donors.

View
08 Oct

Microplastics in Bloodstream: The Hidden Link to Cardiovascular and Neurological Disorders

The emerging link between Microplastics in the Bloodstream and their potential role in triggering Cardiovascular and Neurological disorders

View
03 Oct

A New Hope for Type 1 Diabetes: Tackling Blood Sugar Drops with Somatostatin Blockers

While it may take time for this new treatment to become widely available, the potential impact on the lives of those with type 1 diabetes is enormous.

View
26 Sep

What Every Parent Needs to Know About Autism and Pandemic Babies

Contrary to earlier fears, the study found no connection between pandemic-related stress or maternal COVID-19 infection and a rise in autism rates among babies born during the pandemic.

View
05 Aug

Lingering Shadows: The Unseen Battle with Long COVID

The study highlights the urgent need for continued research and development of effective treatments to alleviate the burden of long COVID on individuals and society.

View

-Advertisements-




Trending Now

1.5 Million Bottles Recalled: Is Your ADHD Medication Safe?March 03, 2025
Dressed for Trust: Why Doctors Must Wear White Aprons AgainMarch 03, 2025
India’s Pharma Revolution: Can New Regulatory Reforms Unleash a $42 Billion Industry?March 01, 2025
Pregnant and Pained: Is Paracetamol Poisoning Our Unborn Children?March 01, 2025
Are Your Idlis Poisoning You? The Hidden Dangers of Plastic in Indian KitchensMarch 01, 2025
Stuck in Slow Motion: How Bureaucracy is Choking India’s Pharma DreamFebruary 27, 2025
A New Spine, A New Life: Inside Kerala’s First 3D-Printed Titanium Cage SurgeryFebruary 27, 2025
India’s Newborns Are Dying from Sepsis And No One Is Talking About ItFebruary 27, 2025
Did the Government Force Covid Vaccines Without Responsibility? The Supreme Court Thinks SoFebruary 26, 2025
The Inequality of Survival: Why Some Women Die While Others LiveFebruary 26, 2025
The Corporate Invasion of Indian Hospitals: What It Means for YouFebruary 26, 2025
5 Simple Daily Habits to Keep Your Joints Healthy and Pain-FreeFebruary 25, 2025
Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize MET-X in IndiaFebruary 25, 2025
With only 70 months left to end AIDS why is the urgency missing?February 25, 2025
Drenched in Oil: Is India Cooking Its Way to an Obesity Epidemic?February 25, 2025
Transforming Education: How Online Learning Platforms are Reshaping Study Material for Board and Competitive ExamsFebruary 24, 2025
February 24, 2025
The Dark Side of India’s Pharma Boom: How Banned Drugs Found a New Market in West AfricaFebruary 24, 2025
The Great Indian Medical Education Paradox: More Seats, Fewer Students, Collapsing SystemFebruary 24, 2025
From Science Fiction to Reality: AI Now Detects Blindness Before It StartsFebruary 24, 2025